Characterization of methamphetamine effects on the striatal-nigral dynorphin system

Eur J Pharmacol. 1988 Oct 11;155(1-2):11-8. doi: 10.1016/0014-2999(88)90397-4.

Abstract

Multiple high doses of methamphetamine (METH) induced 200-300% increases in the concentration of striatal and nigral dynorphin-like immunoreactivity (DLI). Increases in striatal and nigral DLI levels also were seen within 6 h following a single administration. The changes in the striatal-nigral dynorphin system had subsided 48 h after either acute or multiple treatments with METH. Selective lesioning of the nigral-striatal dopamine pathway blocked the effects; thus, the METH-induced changes appeared to be mediated by dopamine released from the nigral-striatal dopamine projection. Administration of the METH analog, 3,4-methylenedioxymethamphetamine, appeared to alter striatal and nigral DLI concentrations in a manner similar to that of METH.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • 3,4-Methylenedioxyamphetamine / analogs & derivatives
  • 3,4-Methylenedioxyamphetamine / metabolism
  • 3,4-Methylenedioxyamphetamine / pharmacology
  • Animals
  • Corpus Striatum / drug effects
  • Corpus Striatum / metabolism*
  • Dynorphins / physiology*
  • Hydroxydopamines / pharmacology
  • Male
  • Methamphetamine / metabolism
  • Methamphetamine / pharmacology*
  • N-Methyl-3,4-methylenedioxyamphetamine
  • Oxidopamine
  • Radioimmunoassay
  • Rats
  • Rats, Inbred Strains
  • Substantia Nigra / drug effects
  • Substantia Nigra / metabolism*
  • Sympathectomy, Chemical

Substances

  • Hydroxydopamines
  • Methamphetamine
  • 3,4-Methylenedioxyamphetamine
  • Dynorphins
  • Oxidopamine
  • N-Methyl-3,4-methylenedioxyamphetamine